28 Feb

MRCF invests in San Diego ophthalmic biotech company, clinical trials to take place in Australia

The MRCF has a trainee/secondee program, whereby Member Institutes or allied public sector initiatives can nominate staff members to work within the Investment Manager for periods ranging from 1 – 6 months. Read Article

19 Feb

Australian biotech company launched with AU$7m investment to develop therapies for treating obesity

The Company has been founded to develop new therapies to target conditions relating to an unhealthy Western diet, including serious and highly prevalent diseases associated with obesity. The company will initially focus on treatments for the emerging epidemic of a liver disease termed ‘NASH’ (non-alcoholic steatohepatitis). Read Article

13 Feb

Auspherix Awarded Innovate UK Grant to Treat Life-threatening Respiratory Infections

“With the global spread of antimicrobial resistance (AMR) and the fact that no new class of antibiotic has been discovered in over 30 years, patients with drug-resistant lung infections are particularly vulnerable,” said Dr Neil Miller, CEO of Auspherix. Read Article

13 Dec

New Zealand biomedical discovery set to revolutionise the global pain relief drug market

Kea Therapeutics is a spin-out of the Auckland Cancer Society Research Centre (ACSRC) and Faculty of Medical and Health Sciences Waikato Clinical Campus, University of Auckland. It will use the investment from the MRCF, including co-investment and support from Auckland UniServices Limited’s University of Auckland Inventors Fund to advance the clinical development of a new […] Read Article

27 Nov

Q-Sera’s innovative blood clotting technology patent granted in China

Michael Grant, CEO of Q-Sera, says, “China is a growing market for biochemistry testing tubes and a major interest for companies in the tube manufacturing sector including local, regional and global companies. Q-Sera tubes will allow rapid expansion into this growing market and bring benefits to a wide range of patients.” Read Article

11 Nov

Australian investors lead AU$60m raise to develop new technology

The technology has been developed by EBR Systems and is a wireless cardiac pacing system for heart failure. Read Article

03 Nov

Osprey Medical and AKI highlighted at largest international cardiovascular conference TCT 2017

Presented at TCT’s CI-AKI: Preventive Measures That Work lunch symposium, three of the talks focused on the importance of contrast reduction as a component to reducing the risk of AKI in the cardiac catheterization lab. The key presentations included “The current state of CI-AKI in the cath lab” (Dr. Roxanne Mehran), “Effective methods for reducing […] Read Article

23 Oct

Q-Sera’s ground-breaking blood clotting technology presented at leading scientific conference in South Africa

The annual Congress sees leading clinical and medical experts gather from around the world to learn about, and share, the latest breakthroughs in clinical science and laboratory medicine. Read Article